Highland Therapeutics’ subsidiary starts phase 2 Trial for HLD100 in pediatric ADHD patients
Utilizing Ironshore’s proprietary delayed-release and extended-release technology, DELEXIS, HLD100 is intended for nighttime dosing and is designed to control ADHD symptoms and improve functioning immediately upon awakening and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.